Drug intelligence / Profile preview

litapiprant

Development stage: Phase 1
Lead developer: Sunshine Lake Pharma
Modality: Small Molecules
Administration: Oral

Overview

Litapiprant is a small molecule drug that acts as an antagonist of the chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2), also known as the prostaglandin D2 (PGD2) receptor. It is being developed primarily for the treatment of asthma and other allergic airway inflammatory conditions. The drug works by inhibiting CRTH2/PGD2 receptor signaling, which plays a key role in mediating inflammation and immune responses associated with allergic diseases. Litapiprant is under development by Sunshine Lake Pharma[1][3][5].

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on litapiprant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on litapiprant.

Explore the full profile